Connexion du logiciel ViroScore®-HIV (CE IVD) à Nadis disponible

Nous avons le plaisir de vous annoncer que l’intégration du logiciel ViroScore®-HIV (CE IVD) à la plateforme Nadis est disponible. Cette intégration permet à l’ensemble des utilisateurs Nadis de bénéficier de fonctionnalités avancées pour le génotypage du VIH: Synchronisation bidirectionnelle des do…

Read more

ABL Announces Distribution Agreement with Hydrox SIA in Latvia

Advanced Biological Laboratories (ABL) S.A. and ILC – Hydrox SIA are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Latvia. See current channel partners.

Read more

TGen and ABL pursue global rollout of advanced TB test

FLAGSTAFF, Ariz., LUXEMBOURG City, Luxembourg — In an important step toward eradicating tuberculosis (TB), the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has signed a licensing agreement with an international biomedical firm, Advanced Biological Laboratories (ABL…

Read more

Early access program launched on ABL Life Science products!

ABL launches its Life Science division and starts the distribution of disruptive molecular biology instruments to be used for research purposes – Join our Early Access Program and get 30% discount on all UltraGene real time PCR systems! More information Join the program

Read more

ABL and Xi’an Tianlong Science and Technology Co., Ltd announce a distribution agreement conferring to ABL the ability to commercialize innovative real-time amplification (qPCR) instruments and reagents as well as RNA/DNA automated extraction solutions

LUXEMBOURG VILLE, Luxembourg, December 27th, 2018 — Advanced Biological Laboratories (ABL) S.A. today announced the official launch of its Life Science division to provide on a worldwide basis, innovative solutions around molecular biology. It is also proud to announce the execution of a distr…

Read more

New poster on HIV resistance to be presented at the HIV DART 2018 congress

We are pleased to announce that a new poster communication entitled “Clinical resistance to dolutegravir assessed by next-generation sequencing in patients pre-exposed to raltegravir” will be presented at the HIV DART and Emerging Viruses 2018 congress in Miami (USA, 27-29 November 2018)…

ABL Welcomes you at MEDICA 2018

ABL will be attending the next MEDICA forum in Dusseldorf from 12 – 15 November 2018: Hall 3 / B70 Our team will provide information on our portfolio: Laboratories, virologists and microbiologists: DeepChek® Assays (Genotyping & Drug Resistance) UltraGene® Assays (Viral Load Detection) Dee…

Read more